1. No category

Education Satellite Symposium at the ADA 75th Scientific Sessions 2015
Medtelligence
1070 Highway 34, Suite 208
Matawan, NJ 07747
Comprehensive Management of DM: Focus on
SGLT2 Inhibitors and Combination Therapy
Emerging Concepts of Renal Effects
Friday, June 5, 2015
6:30 PM – 9:30 PM
Dinner will be served
Renaissance Boston Waterfront Hotel
Pacific Grand Ballroom
606 Congress Street
Boston, MA 02210
Zachary T. Bloomgarden, MD, MACE, Chair
ATTENDANCE
IS LIMITED!
Registration for this event
must be submitted online at:
https://www4.cmrreg.com/
ada2015/
Or scan this QR code
to register:
Comprehensive Management of DM:
Focus on SGLT2 Inhibitors and
Combination Therapy
Emerging Concepts of Renal Effects
Friday, June 5, 2015
6:30 PM – 9:30 PM CME Dinner Symposium
Renaissance Boston Waterfront Hotel
606 Congress Street, Boston, MA 02210
Clinical Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, NY
Yehuda Handelsman, MD, FACP, FACE, FNLA, Chair
Medical Director and Principal Investigator
Metabolic Institute of America
Tarzana, CA
Stefano Del Prato, MD
Professor of Endocrinology
Chief, Section of Diabetes and Metabolic Diseases
University of Pisa
Pisa, Italy
Lawrence A. Leiter, MD, FRCPC, FACP, FAHA
Professor of Medicine and Nutritional Sciences
University of Toronto
Toronto, ON, Canada
You may view the Agenda
and program information at:
http://metabolicfoundation.com/
ADA2015
Matthew R. Weir, MD
Americans with Disabilities Act
Professor and Director of Nephrology
University of Maryland School of Medicine
Baltimore, MD
Event staff will be glad to assist you with any special needs
(ie, physical, dietary, etc). Please contact Chris Archibald
prior to the live event at 732-977-5887.
Medtelligence
SM
Jointly provided by PESI, Inc., Metabolic Endocrine Education Foundation, and Medtelligence
Register online at: https://www4.cmrreg.com/ada2015
This activity is supported by an educational grant from AstraZeneca
Comprehensive Management of DM: Focus on SGLT2 Inhibitors and Combination Therapy
Emerging Concepts of Renal Effects
Program Format
The program will intersperse panel discussions with didactic lectures, leaving time for Q&A and audience participation throughout
the activity.
Program Description
The contemporary approach to managing diabetes, exemplified by the practice recommendations of several medical societies, uses
early intervention with combination medications to reach treatment goals swiftly and safely. For many years, the contribution of the
kidney to whole body glucose homeostasis, the role of the kidney in diabetes pathophysiology, and its potential in the management
of diabetes has been largely unrecognized. Novel agents like the renal sodium-glucose linked transporter-2 (SGLT2) inhibitors have
recently been developed to effectively manage the hyperglycemia of type 2 diabetes (T2DM) and are also associated with weight
loss and reduction of blood pressure. Although early reports have raised questions about potential deleterious effects on kidney
function, further observations specifically among persons having, or at risk of having, diabetic renal disease, have shown reduction
in albuminuria and in rates of deterioration in renal function, actually suggesting potential nephroprotection. Meanwhile, there is
emerging information that another class of agents used in the treatment of T2DM, the dipeptidyl peptidase (DPP) 4 inhibitors, may
also have beneficial effects on kidney function.
The overall objective of this CME program is to describe the management of diabetes, discussing early combination therapy and
how to achieve goals safely without hypoglycemia or weight gain. The varied effects of newer agents, including SGLT2 inhibitors
and incretin-based therapy (DPP4 inhibitors and GLP1 receptor agonists), and their potential combinations will be evaluated. The
efficacy of such approaches in glycemic control, the effects on weight and blood pressure, and emerging information about potential
positive effects on renal function will be addressed, providing expert insight on the implications of these findings for the long-term
management of diabetes.
Target Audience
Diabetologists, endocrinologists, cardiologists, family physicians, internists, dieticians, nurse practitioners, pharmacists, and other
health care professionals who are interested in diabetes and obesity.
Objectives
• Discuss contemporary approaches to managing diabetes
• Describe the role of the kidney in energy metabolism and its contribution, through gluconeogenesis and glucose reabsorption
via the SGLT2, to glucose levels
• Describe the mechanism of SGLT2 inhibitor (SGLT2i) therapy, its efficacy, and its potential effect on weight, blood pressure,
and the kidneys
• Explain the role of combination therapy, in particular incretin-based therapy and SGLT2i, with metformin (as tolerated) in
managing diabetes
• Analyze the effect of SGLT2i on the kidney, with a focus on potential nephroprotection
Agenda
6:30 PM
Registration and Dinner
7:00 Welcome and Introductions
Zachary T. Bloomgarden, MD and Yehuda Handelsman, MD
7:10 Contribution of the Kidney to Whole Body Glucose Homeostasis: A Critical Re-evaluation
Zachary T. Bloomgarden, MD
7:40 SGLT2 Inhibitors and the Kidney: Mechanism and Clinical Efficacy
Lawrence A. Leiter, MD
8:05 SGLT2 Inhibitors and the Kidney: The Potential for Nephroprotection
Matthew R. Weir, MD
8:30 Exploring Mono- and Dual Therapy - Implications for Kidney Function
Stefano Del Prato, MD
8:55 Panel Discussion and Q&A: Contemporary Approach to the Management of Diabetes
Moderators: Zachary T. Bloomgarden, MD and Yehuda Handelsman MD
9:20Conclusions
9:30 PM
Adjourn
ATTENDANCE IS LIMITED! REGISTER ONLINE.
Go to https://www4.cmrreg.com/ada2015/ to register for the American Diabetes
Association’s 75th Scientific Sessions and our Corporate Symposium.
For more information, email [email protected].
You may view the Agenda and program information at: http://metabolicfoundation.com/ADA2015
If you have already registered for Scientific Sessions, sign in as a Non-Member using your e-mail address or as
a Member using your e-mail address or professional member ID # and zip code and you will be able to add the
Corporate Symposium to your existing registration. Proceed through the registration pages to the Corporate
Symposia, and after making your selection, click ‘Next Page’ until you see your confirmation summary. You will
receive a revised e-mail confirmation.
If you have any questions regarding your registration please contact the ADA Registration Customer Care Center
at (866) 290-9910 (toll free US & Canada) or (415) 268-2086 (International) Monday-Friday, between the hours of
9 a.m.-9 p.m. ET or via the ADA Support Center at http://ada.cmrushelp.com.
Accreditation Information
Physicians
This live activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation
Council for Continuing Medical Education through the joint providership of PESI, Inc. and Metabolic Endocrine Education
Foundation (MEEF). PESI, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AMA PRA Designation Statement
PESI, Inc. designates this live educational activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should only
claim credit commensurate with the extent of their participation in the activity.
Family Physicians
This program has been submitted for approval by the AAFP.
Pharmacists
For the purpose of recertification, the American Council of Pharmacy Education (ACPE) accepts AMA PRA Category 1 Credit™
issued by organizations accredited by the ACCME. This activity provides 2.5 credit hours.
International CME
International Physicians are formally eligible for AMA PRA Category 1 Credit™.
Physician Assistants
AAPA accepts Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ for the PRA
from organizations accredited by ACCME.
Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by
organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured
learning activities. This activity provides 2.5 credit hours.
CA Nurses
Aspen CME Services is approved by the California Board of Registered Nursing, Provider number CEP14739, for
2.5 contact hours.
Registered Dieticians
This program has been submitted for approval by the Commission on Dietetic Registration.
Satisfactory Completion for credits: All attendees must have completed and turned in a course attendance/evaluation form prior to
leaving the conference. Each session claimed for credit must be attended in its entirely.
Comprehensive Management of DM: Focus on SGLT2 Inhibitors and Combination Therapy
Emerging Concepts of Renal Effects
Program Format
The program will intersperse panel discussions with didactic lectures, leaving time for Q&A and audience participation throughout
the activity.
Program Description
The contemporary approach to managing diabetes, exemplified by the practice recommendations of several medical societies, uses
early intervention with combination medications to reach treatment goals swiftly and safely. For many years, the contribution of the
kidney to whole body glucose homeostasis, the role of the kidney in diabetes pathophysiology, and its potential in the management
of diabetes has been largely unrecognized. Novel agents like the renal sodium-glucose linked transporter-2 (SGLT2) inhibitors have
recently been developed to effectively manage the hyperglycemia of type 2 diabetes (T2DM) and are also associated with weight
loss and reduction of blood pressure. Although early reports have raised questions about potential deleterious effects on kidney
function, further observations specifically among persons having, or at risk of having, diabetic renal disease, have shown reduction
in albuminuria and in rates of deterioration in renal function, actually suggesting potential nephroprotection. Meanwhile, there is
emerging information that another class of agents used in the treatment of T2DM, the dipeptidyl peptidase (DPP) 4 inhibitors, may
also have beneficial effects on kidney function.
The overall objective of this CME program is to describe the management of diabetes, discussing early combination therapy and
how to achieve goals safely without hypoglycemia or weight gain. The varied effects of newer agents, including SGLT2 inhibitors
and incretin-based therapy (DPP4 inhibitors and GLP1 receptor agonists), and their potential combinations will be evaluated. The
efficacy of such approaches in glycemic control, the effects on weight and blood pressure, and emerging information about potential
positive effects on renal function will be addressed, providing expert insight on the implications of these findings for the long-term
management of diabetes.
Target Audience
Diabetologists, endocrinologists, cardiologists, family physicians, internists, dieticians, nurse practitioners, pharmacists, and other
health care professionals who are interested in diabetes and obesity.
Objectives
• Discuss contemporary approaches to managing diabetes
• Describe the role of the kidney in energy metabolism and its contribution, through gluconeogenesis and glucose reabsorption
via the SGLT2, to glucose levels
• Describe the mechanism of SGLT2 inhibitor (SGLT2i) therapy, its efficacy, and its potential effect on weight, blood pressure,
and the kidneys
• Explain the role of combination therapy, in particular incretin-based therapy and SGLT2i, with metformin (as tolerated) in
managing diabetes
• Analyze the effect of SGLT2i on the kidney, with a focus on potential nephroprotection
Agenda
6:30 PM
Registration and Dinner
7:00 Welcome and Introductions
Zachary T. Bloomgarden, MD and Yehuda Handelsman, MD
7:10 Contribution of the Kidney to Whole Body Glucose Homeostasis: A Critical Re-evaluation
Zachary T. Bloomgarden, MD
7:40 SGLT2 Inhibitors and the Kidney: Mechanism and Clinical Efficacy
Lawrence A. Leiter, MD
8:05 SGLT2 Inhibitors and the Kidney: The Potential for Nephroprotection
Matthew R. Weir, MD
8:30 Exploring Mono- and Dual Therapy - Implications for Kidney Function
Stefano Del Prato, MD
8:55 Panel Discussion and Q&A: Contemporary Approach to the Management of Diabetes
Moderators: Zachary T. Bloomgarden, MD and Yehuda Handelsman MD
9:20Conclusions
9:30 PM
Adjourn
ATTENDANCE IS LIMITED! REGISTER ONLINE.
Go to https://www4.cmrreg.com/ada2015/ to register for the American Diabetes
Association’s 75th Scientific Sessions and our Corporate Symposium.
For more information, email [email protected].
You may view the Agenda and program information at: http://metabolicfoundation.com/ADA2015
If you have already registered for Scientific Sessions, sign in as a Non-Member using your e-mail address or as
a Member using your e-mail address or professional member ID # and zip code and you will be able to add the
Corporate Symposium to your existing registration. Proceed through the registration pages to the Corporate
Symposia, and after making your selection, click ‘Next Page’ until you see your confirmation summary. You will
receive a revised e-mail confirmation.
If you have any questions regarding your registration please contact the ADA Registration Customer Care Center
at (866) 290-9910 (toll free US & Canada) or (415) 268-2086 (International) Monday-Friday, between the hours of
9 a.m.-9 p.m. ET or via the ADA Support Center at http://ada.cmrushelp.com.
Accreditation Information
Physicians
This live activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation
Council for Continuing Medical Education through the joint providership of PESI, Inc. and Metabolic Endocrine Education
Foundation (MEEF). PESI, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AMA PRA Designation Statement
PESI, Inc. designates this live educational activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should only
claim credit commensurate with the extent of their participation in the activity.
Family Physicians
This program has been submitted for approval by the AAFP.
Pharmacists
For the purpose of recertification, the American Council of Pharmacy Education (ACPE) accepts AMA PRA Category 1 Credit™
issued by organizations accredited by the ACCME. This activity provides 2.5 credit hours.
International CME
International Physicians are formally eligible for AMA PRA Category 1 Credit™.
Physician Assistants
AAPA accepts Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ for the PRA
from organizations accredited by ACCME.
Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by
organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured
learning activities. This activity provides 2.5 credit hours.
CA Nurses
Aspen CME Services is approved by the California Board of Registered Nursing, Provider number CEP14739, for
2.5 contact hours.
Registered Dieticians
This program has been submitted for approval by the Commission on Dietetic Registration.
Satisfactory Completion for credits: All attendees must have completed and turned in a course attendance/evaluation form prior to
leaving the conference. Each session claimed for credit must be attended in its entirely.